Top in hem/onc: Pan-tumor liquid biopsy test, retiring from medicine

The FDA has approved a new pan-tumor liquid biopsy test that can help guide treatment decisions for patients with solid tumors. It was the top story in hematology/oncology last week.

Another top story was about guidance for physicians who are considering retirement.

Read these and more top stories in hematology/oncology below:

FDA approves Foundation Medicine pan-tumor liquid biopsy test

The FDA recently approved FoundationOne Liquid CDx (Foundation Medicine), a comprehensive pan-tumor liquid biopsy test. Read more.

Determining when it is your time to retire

Nicholas J. Petrelli, MD, FACS, Bank of America endowed medical director of ChristianaCare’s Helen F. Graham Cancer Center & Research Institute and associate director of translational research at Wistar Cancer Institute, offers suggestions on what physicians should consider when thinking about retiring from a career in medicine. Read more.

Depression, anxiety in cancer survivors: An underrecognized ‘emotional crash’

The successful completion of active treatment is an important milestone for anyone who has lived with cancer. However, being cancer-free does not always bring the peace of mind patients might expect. Read more.

Cytotoxic chemotherapy not linked to adverse COVID-19 outcomes

Recent cytotoxic chemotherapy treatment did not appear to be associated with adverse COVID-19 outcomes for patients with cancer, according to results of a retrospective study published in Journal of Clinical Oncology. Read more.

Phase 3 trial in advanced AML misses primary endpoint

A randomized phase 3 trial designed to evaluate the addition of enasidenib (Idhifa, Bristol-Myers Squibb) to best supportive care for certain patients with acute myeloid leukemia failed to meet its primary endpoint, according to the agent’s manufacturer. Read more.